4.26

3.18% -0.14

After Hours: 4.35 0.09 +2.11%

C 4 Therapeutics Inc (CCCC)

Overview News Price History Option Chain Financials Discussions Forecast

C 4 Therapeutics Inc stock is traded at $4.26, with a volume of 20.14M. It is down -3.18% in the last 24 hours and up +22.06% over the past month. C4 Therapeutics Inc is a clinical-stage biopharmaceutical company dedicated to delivering on the promise of targeted protein degradation science to create a new generation of medicines that transforms patient's lives. The Company is progressing targeted oncology programs through clinical studies and leveraging its TORPEDO platform to efficiently design and optimize small-molecule medicines to address difficult-to-treat diseases. The degrader medicines of the company are designed to harness the body's natural protein recycling system to rapidly degrade disease-causing proteins, offering the potential to overcome drug resistance, and drug undruggable targets and improve patient outcomes. Its pipeline is Cemsidomide, CFT8919, and other discovery products.

Previous Close:

$4.40

Open:

$4.45

24h Volume:

20.14M

Relative Volume:

6.67

Market Cap:

$471.02M

Revenue:

$34.86M

Net Income/Loss:

$-103.80M

P/E Ratio:

-3.5968

EPS:

-1.1844

Net Cash Flow:

$-96.02M

1W Performance:

+2.65%

1M Performance:

+22.06%

6M Performance:

+100.94%

1Y Performance:

+180.26%

1-Day Range:

$4.14

$4.575

1-Week Range:

$3.99

$4.575

52-Week Range:

$1.395

$4.5981

C 4 Therapeutics Inc Stock (CCCC) Company Profile

Name

C 4 Therapeutics Inc

Sector

Healthcare (1096)

Industry

Biotechnology (615)

Phone

(617) 231-0700

Address

490 ARSENAL WAY, WATERTOWN

Employee

104

Twitter

Next Earnings Date

2026-08-06

Latest SEC Filings

CCCC's Discussions on Twitter

Compare CCCC vs VRTX, REGN, ARGX, ALNY, RVMD

Stocks	Price	Market Cap	Revenue	Net Income	Cash Flow	EPS
CCCC C 4 Therapeutics Inc	4.26	486.50M	34.86M	-103.80M	-96.02M	-1.1844
VRTX Vertex Pharmaceuticals Inc	491.34	121.87B	12.34B	4.34B	3.71B	16.87
REGN Regeneron Pharmaceuticals Inc	632.90	65.01B	14.92B	4.42B	3.79B	41.04
ARGX Argen X Se Adr	887.18	55.26B	4.16B	1.29B	734.26M	19.58
ALNY Alnylam Pharmaceuticals Inc	291.37	39.14B	4.29B	577.22M	641.34M	4.2086
RVMD Revolution Medicines Inc	182.08	37.88B	742.00K	-1.37B	-1.07B	-7.0731

C 4 Therapeutics Inc Stock (CCCC) Upgrades & Downgrades

Date	Action	Analyst	Rating Change
Dec-02-25	Initiated	TD Cowen	Buy
Sep-17-25	Initiated	Barclays	Overweight
Sep-15-25	Upgrade	Stephens	Equal-Weight → Overweight
Sep-04-25	Initiated	Guggenheim	Buy
Dec-19-24	Upgrade	Wells Fargo	Equal Weight → Overweight
Nov-18-24	Initiated	Stephens	Equal-Weight
Jan-29-24	Upgrade	JP Morgan	Underweight → Neutral
Dec-13-23	Upgrade	Stifel	Hold → Buy
Feb-24-23	Upgrade	Credit Suisse	Underperform → Neutral
Feb-24-23	Downgrade	JP Morgan	Neutral → Underweight
Nov-04-22	Downgrade	JP Morgan	Overweight → Neutral
Oct-11-22	Initiated	Morgan Stanley	Underweight
Apr-28-22	Initiated	Credit Suisse	Underperform
Apr-11-22	Downgrade	BofA Securities	Buy → Neutral
Mar-10-22	Initiated	JP Morgan	Overweight
Feb-11-22	Resumed	BMO Capital Markets	Outperform
Feb-10-22	Initiated	Wells Fargo	Equal Weight
Nov-23-21	Initiated	BofA Securities	Buy
Oct-14-21	Initiated	SVB Leerink	Mkt Perform
Sep-30-21	Initiated	Stifel	Hold
Jun-04-21	Initiated	H.C. Wainwright	Buy
Mar-31-21	Initiated	BMO Capital Markets	Outperform
Oct-28-20	Initiated	UBS	Buy
Oct-27-20	Initiated	BMO Capital Markets	Outperform
Oct-27-20	Initiated	Jefferies	Buy

View All

C 4 Therapeutics Inc Stock (CCCC) Latest News

08:39 AM

C4 Therapeutics (NASDAQ: CCCC) director receives 62,000 stock options at $4.25 - Stock Titan

08:39 AM

08:31 AM

Director Steven Hoerter gets 62,000 C4 Therapeutics (CCCC) options at $4.25 - Stock Titan

08:31 AM

04:49 AM

Contineum Therapeutics (CTNM) elects Class II directors, ratifies Ernst & Young as 2026 auditor - Stock Titan

04:49 AM

04:37 AM

C4 Therapeutics (NASDAQ: CCCC) director receives grant of 62,000 stock options - Stock Titan

04:37 AM

04:36 AM

Form 4 C4 Therapeutics Inc For: 26 June By Investing.com - Investing.com Canada

04:36 AM

04:31 AM

[Form 4] C4 Therapeutics, Inc. Insider Trading Activity - Stock Titan

04:31 AM

04:30 AM

Nektar Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - PR Newswire

04:30 AM

04:29 AM

Director at C4 Therapeutics (CCCC) granted 62,000 stock options at $4.25 - Stock Titan

04:29 AM

04:28 AM

C4 Therapeutics (CCCC) director awarded 62,000 stock options at $4.25 strike - Stock Titan

04:28 AM

04:27 AM

C4 Therapeutics (CCCC) director receives 62,000-share stock option award - Stock Titan

04:27 AM

04:26 AM

C4 Therapeutics (CCCC) director receives grant of 62,000 stock options - Stock Titan

04:26 AM

04:16 AM

Dyne Therapeutics (NASDAQ: DYN) CFO sells 2,362 shares to cover taxes - Stock Titan

04:16 AM

09:49 AM

Are medical stocks lagging C4 Therapeutics (CCCC) this year? - MSN

09:49 AM

08:40 AM

Dyne Therapeutics (DYN) director-linked funds sell 267,760 shares - Stock Titan

08:40 AM

06:00 AM

IDEAYA Biosciences Announces Inducement Grants under Nasdaq Listing Rule 5635(c)(4) - PR Newswire

06:00 AM

Jun 25, 2026

EcoR1, Oleg Nodelman disclose 9.0% stake in Fulcrum (NASDAQ: FULC) - Stock Titan

Jun 25, 2026

Jun 24, 2026

C4 Therapeutics Shareholders Back Directors, Pay and Auditors - TipRanks

Jun 24, 2026

C4 Therapeutics (NASDAQ: CCCC) investors approve directors, pay and stock plan change - Stock Titan

Jun 24, 2026

C4 Therapeutics (CCCC) AGM 2026 Summary - Quartr

Jun 24, 2026